Protocol ALL-11:Treatment study protocol of the Dutch Childhood Oncology Group for children and adolescents (1-19 year) with newly diagnosed acute lymphoblastic leukemia - DCOG Protocol ALL-11

Stichting Kinderoncologie Nederland0 个研究点目标入组 770 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•1. Newly diagnosed patients with T-lineage or precursor-B lineage ALL (patients with mature B-ALL are not eligible)
•2. Age between > 1 and < 19 years
•3. Informed consent signed by parents/guardians and patient if 12 years or older
•4. Diagnosis ALL confirmed by DCOG laboratory
•5. Patient should be treated in a Dutch Childhood Oncology Centre
•6. Patient should be >3 months settled in The Netherlands at diagnosis

•1. Age * 19 years at diagnosis
•2. Age < 366 days at diagnosis (infant ALL); these patients are eligible for the Interfant protocol
•3. Patients with secondary ALL
•4. Patients with mature B-ALL (immunophenotypical or documented presence of karyotype t(8;14), t(2;8), t(8;22) and breakpoint as in B-ALL)
•5. Patients with relapsed ALL
•6. Pre-existing contra-indications for treatment according to (parts of) protocol ALL-11.
•7. Essential data missing (in consultation with the protocol chairman)
•8. Treatment with systemic corticosteroids and/or cytostatics in a 4-week interval prior to diagnosis. One exception is the use of corticosteroids as emergency treatment.
•9. Patients with Ph-positive ALL (documented presence of t(9;22)(q34;q11) and/or of the BCR/ABL fusion transcript). These patients will be transferred to the EsPhALL protocol in induction according to the guidelines of the EsPhALL protocol.

发起方

Stichting Kinderoncologie Nederland